GlaxoSmithKline places its shingles vaccine ... Another company developing a vaccine for herpes zoster is US biotech Curevo Vaccine, whose adjuvanted subunit vaccine CRV-101 is in early-stage ...

GlaxoSmithKline Pharmaceuticals Limited ... In 2022-23, the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults who are 50 years ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

Herpes zoster vaccine Shingrix for shingles has been the main driver of GSK’s revenue growth for some time, accounting for £1.7 billion ($2.1 billion) of the company’s £14 billion in sales ...

(Reuters) - GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot ...

HALIFAX - Nova Scotia’s Progressive Conservatives promised on Tuesday to introduce a universal shingles vaccine program for people 65 and older if re-elected Nov. 26, the latest in a series of ...

Multiple children were injured in an Israeli bombing near a vaccination clinic in northern Gaza, aid organizations reported, as the second round of a campaign to vaccinate children against polio ...